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bjectives The aim of this study was to assess the long-term safety and efﬁcacy of the CYPHER
Cordis, Johnson and Johnson, Bridgewater, New Jersey) sirolimus-eluting coronary stent (SES) in
ercutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI).
ackground Concern over the safety of drug-eluting stents implanted during PCI for STEMI remains, and
ong-term follow-up from randomized trials are necessary. TYPHOON (Trial to assess the use of the cYPHer
irolimus-eluting stent in acute myocardial infarction treated with ballOON angioplasty) randomized 712 pa-
ients with STEMI treated by primary PCI to receive either SES (n  355) or bare-metal stents (BMS) (n  357).
he primary end point, target vessel failure at 1 year, was signiﬁcantly lower in the SES group than in the BMS
roup (7.3% vs. 14.3%, p  0.004) with no increase in adverse events.
ethods A 4-year follow-up was performed. Complete data were available in 501 patients (70%),
nd the survival status is known in 580 patients (81%).
esults Freedom from target lesion revascularization (TLR) at 4 years was signiﬁcantly better in the SES
roup (92.4% vs. 85.1%; p  0.002); there were no signiﬁcant differences in freedom from cardiac death
97.6% and 95.9%; p  0.37) or freedom from repeat myocardial infarction (94.8% and 95.6%; p  0.85)
etween the SES and BMS groups. No difference in deﬁnite/probable stent thrombosis was noted at 4
ears (SES: 4.4%, BMS: 4.8%, p  0.83). In the 580 patients with known survival status at 4 years, the all-
ause death rate was 5.8% in the SES and 7.0% in the BMS group (p  0.61).
onclusions In the 70% of patients with complete follow-up at 4 years, SES demonstrated sustained efﬁcacy
o reduce TLR with no difference in death, repeat myocardial infarction or stent thrombosis. (The Study to
ssess AMI Treated With Balloon Angioplasty [TYPHOON]; NCT00232830) (J Am Coll Cardiol Intv 2011;4:
4–23) © 2011 by the American College of Cardiology Foundationrom the *Cochin Hospital, Assistance-Publique Hôpitaux de Paris, Paris Descartes University and INSERM U 970, Paris,
rance; †Henri Mondor Hospital, Assistance-Publique Hôpitaux de Paris, France; ‡Polyclinique des Fleurs, Ollioules, France;
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15rimary percutaneous coronary intervention (PCI) is the
ptimal reperfusion therapy for ST-segment elevation myo-
ardial infarction (STEMI) patients (1,2), leading to a
ignificant reduction in mortality rates when compared with
harmacological therapy alone (3). A strategy of primary
CI with bare-metal stent (BMS) when compared with
alloon angioplasty alone reduces the need for repeat
evascularization without any impact on mortality (4).
See page 39
everal randomized trials with 1-year follow-up have dem-
nstrated the effectiveness of drug-eluting stents (DES) in
educing the rate of repeat revascularization at 1 year
ompared with BMS (5–14). However, the long-term safety
f DES in this setting is debated. Few studies have reported
onger follow-up (15–17). Registries have delivered conflict-
ng results regarding the late occurrence of death or stent
hrombosis (18–21). Therefore, the use of DES during
rimary PCI remains a controversial issue, and long-term
ollow-up of randomized trials is of paramount importance.
We report the 4-year follow-up of TYPHOON (Trial to
ssess the use of the cYPHer sirolimus-eluting stent in acute
yocardial infarction treated with ballOON angioplasty),
hich compared the use of SES with any BMS during
rimary PCI for STEMI.
ethods
nitial trial design. The design and 1-year results of the
YPHOON have been reported previously (6). Patients
ere eligible for the trial if their symptoms began 12 h
efore catheterization and if the electrocardiogram showed
T-segment elevation. Clinical criteria for exclusion in-
luded the administration of fibrinolytic agents for the index
nfarction, overt acute heart failure, a previously docu-
ented left ventricular ejection fraction of 30%, and
revious myocardial infarction (MI). The trial protocol
equired visualization of the culprit lesion before random-
zation. The target lesion had to be 30 mm and located in
native coronary artery with a reference-vessel diameter of
.25 to 3.50 mm. Patients were randomly assigned to
reatment groups in a 1:1 ratio and received either an SES
CYPHER stent or CYPHER SELECT stent, Cordis,
Policlinico S. Matteo di Pavia, Pavia, Italy; Hopital Antoine Beclere, Clamart,
rance; ¶Mayday University Hospital, London, United Kingdom; #Hopital Guil-
aume et René Laennec–CHU de Nantes, Nantes, France; **Slaskie Centrum Chorob
erca, Zabrze, Poland; ††University Medical Center, Heart Lung Center, Utrecht,
he Netherlands; ‡‡Royal Perth Hospital, Perth, Australia; §§Clinique Pasteur,
oulouse, France;  Clinique du Millénaire, Montpellier, France; ¶¶Univer-
itëtsklinikum Freiburg, Freiburg, Germany; ##Hopital Rangueil, Toulouse, France;
**Pauls Stradins University Hospital, Riga, Latvia; †††Semmelweis University,
udapest, Hungary; ‡‡‡Cordis Corporation (Johnson & Johnson), Waterloo, Bel-
ium; and the §§§Hopital Lariboisiere, Paris, France. The TYPHOON trial was an
nvestigator-initiated trial sponsored by Cordis Corporation, a Johnson & Johnson aohnson and Johnson, Bridgewater, New Jersey) or any
ommercially available BMS.
The primary end point was target vessel failure, a com-
osite of target vessel revascularization (TVR), recurrent
I, or target vessel–related death at 1 year.
our-year extension. The trial was closed in November
005. Because of concern over long-term safety issues with
ES, an extension to have up to 5-year follow-up was
ubmitted to the ethics committees of the participating
nstitutions as of August 2007. Because the trial had been
losed, the centers were contacted and had to agree to
articipate in the extension, and a new informed consent
ad to be obtained from the patients for the long-term
ollow-up. In case of death, informed consent had to be
btained from a legally authorized representative. The trial
as terminated after 4 years of follow-up, due to a lower-
han-expected rate of site participation and re-consent by
atients.
A physician office visit at the
rial site was performed at 4
ears  1 month after proce-
ure, consisting of patient re-
onsent, assessment of the an-
ina status (according to both
he Canadian Cardiovascular
ociety Classification of angina
nd the Braunwald Classifica-
ion for unstable), any adverse
vent, medication regimen, and
ny interventional treatment
hat occurred since the previ-
us study contact (e.g., repeat
evascularization). If the pa-
ient could not return to the
rial site, a telephone call was
erformed. In this case, the site
ad to ensure that 2 signed
opies of the informed consent document were received
efore the interview by telephone. If a stent thrombosis
r repeat coronary angiogram or PCI had been per-
ormed, a copy of the procedures was obtained. If the
atient had died between 1 and 4 years after the index
rocedure, attempts were made to obtain written consent
rom a legal representative to use the patient data. If no
ompany. Dr. Spaulding was a member of a Cordis scientific advisory board; has
eceived honorarium from Cordis for speaker’s fees; and has been a full-time employee
f the Cordis Corporation since June 1, 2010. Dr. Varenne is a speaker for Cordis,
oston Scientific, and Abbott. Drs. Cebrian, Wang, and Stoll are full-time employees
f the Cordis Corporation and have Johnson & Johnson stock options. Dr. Fajadet is
consultant for Cordis and Abbott. Dr. Erglis is on the advisory board for Cordis.
r. Hosten is employed by the Cordis Corporation as a consultant. Dr. Henry is part
f the Cordis Exchange program.
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Abbreviations
and Acronyms
ARC  Academic Research
Consortium
BMS  bare-metal stent(s)
CI  confidence interval
DES  drug-eluting stent(s)
HR  hazard ratio
MI  myocardial infarction
PCI  percutaneous
coronary intervention
SES  sirolimus-eluting
stent(s)
STEMI  ST-segment
elevation myocardial
infarction
TLR  target lesion
revascularizationccepted October 15, 2010.
c
d
t
(
o
i
p
F
o
1
i
s
r
c
S
t
m
p
v
e
E
M
w
c
t
e
a
p
p
u
A
R
F
f
e
s
s
a
c
c
p
p
i
a
c
e
i
p
e
a
T
d
4
c
p
p
S
H
r
0
9
(
4
H
M
y
4
9
2
d
w
B
0
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 4 , N O . 1 , 2 0 1 1
J A N U A R Y 2 0 1 1 : 1 4 – 2 3
Spaulding et al.
4-Year Follow-Up of the TYPHOON Trial
16onsent was obtained, only the patient status (alive or
ead) was documented, if known.
Events occurring during the first year, including stent
hrombosis, were initially reported with protocol definitions
6). In the 4-year extension, all events, including those
ccurring during the first year, were adjudicated by an
ndependent clinical events committee with definitions pro-
osed by the Academic Research Consortium (ARC) (22).
urthermore, to comply with the ARC recommendations
n data reporting in PCI trials that were published after the
-year report and because there are differences between the
nitial protocol and ARC definitions, results will be pre-
ented as “efficacy end points” (target lesion and vessel
evascularization) and “safety end points” (all-cause death,
ardiac death, repeat MI, and stent thrombosis).
tatistical methods. All analyses were conducted according
o the intention-to-treat principle. Discrete data were sum-
arized as frequencies, whereas continuous data were ex-
ressed as mean  SD. Fisher exact test (categorical
ariables) and Student t test (continuous variables) were
mployed to analyze differences between the 2 study arms.
vent-free survival curves were generated by the Kaplan-
eier method, and survival between groups was compared
ith the log-rank test. Hazard ratios (HRs) with 95%
onfidence intervals (CIs) were calculated with a propor-
ional hazards model. A 2-sided p value 0.05 was consid-
red significant for all tests.
To assess the impact of missing data, tipping point
nalysis and multiple imputation were performed. Tipping
oint analysis assesses the sensitivity without the need to
ostulate any missing data mechanism and without model
ncertainty. Details of these analyses are given in the Online
ppendix.
esults
igure 1 describes the percentages of patients lost to
ollow-up. No data are available in 55 patients who were
nrolled in centers that refused to participate in the exten-
ion and in 77 patients who were lost to follow-up. The
urvival status (dead or alive) is known in 68 patients who
re alive but refused to participate in the extension and in 11
ases where the patient died and the family refused to give
onsent. Therefore, complete follow-up is available in 501
atients (70%), and the survival status is known in 580
atients (81%). Baseline clinical and procedural character-
stics, before and after procedural quantitative coronary
nalysis were compared between patients with or without
omplete follow-up (Table 1). A lower left ventricular
jection fraction and smaller post-procedural in-stent min-
mal luminal diameter was noted in patients without com-
lete follow-up.
Event-free rates are presented in Figure 2. At 1 year, allfficacy end points (target lesion revascularization [TLR] dnd TVR) significantly favored the SES over the BMS.
here was no difference in safety end points (all-cause
eath, cardiac death, repeat MI, and stent thrombosis). At
years these results are maintained with persistent signifi-
ant differences favoring the SES group for the efficacy end
oints and no difference between groups for the safety end
oints. Freedom from TLR was 95.7% and 88.8% in the
ES and BMS groups, respectively, at 1 year (p  0.0009;
R: 0.378; 95% CI: 0.208 to 0.685) and 92.4% and 85.1%,
espectively, at 4 years (p  0.002; HR: 0.462; 95% CI:
.281 to 0.759). Freedom from cardiac death was 98.0% and
8.3% in the SES and BMS groups at 1-year follow-up
p  0.77; HR: 0.578; 95% CI: 0.372 to 0.899), whereas at
years it was 97.6% and 95.9%, respectively, (p  0.37;
R: 0.667; 95% CI: 0.273 to 1.633). Freedom from repeat
I was 98.9% and 97.7% in the SES and BMS groups at 1
ear (p  0.26; HR: 0.398; 95% CI: 0.237 to 0.668). At
-year follow-up, re-MI freedom rates were 94.8% and
5.6%, respectively (p 0.85; HR: 1.075; 95% CI: 0.505 to
.286).
Figure 3 represents stent thrombosis according to ARC
efinitions. Early definite/probable stent thrombosis rates
ere similar at 1 year although numerically higher in the
MS group (6 in the SES group, 9 in the BMS group, p 
.45; HR: 0.66; 95% CI: 0.24 to 1.84]). No late (between 30
CYPHER
715 Patients Enrolled BMS
3 withdrew consent after procedure
355 712 ti t 357 pa en s
4- Year Follow-up Initiated
26
Patients enrolled in centers that 
refused extension (55) 29  
35 Status unknown (77) 42
36 Alive, no informed consent (68) 32
7 Died, no informed consent (11) 4
251
4-Year Follow-up Completed (501) 
"Complete Follow-up Population" 
70% Follow-up 250   
294
"Survival Status Population" (580)    
81% Follow-up 286
Figure 1. Four-Year Flow Chart
CYPHER (Cordis, Johnson and Johnson, Bridgewater, New Jersey). BMS 
bare-metal stent.ays and 1 year) definite/probable stent thrombosis was
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17oted in either group. Between 1 and 4 years, 5 and 3 cases
f definite/probable stent thrombosis occurred in the SES
nd BMS groups, respectively. No difference in the cumu-
ative rate of definite/probable stent thrombosis was noted
t 4 years (4.4% and 4.8% in the SES and BMS groups,
espectively; p  0.83; HR: 0.91; 95% CI: 0.41 to 2.03).
Table 1. Baseline Clinical and Procedural Characteris
N
Baseline clinical and procedural characteristics
Age, yrs
Male
Diabetes
Hypertension
Hyperlipidemia
Current smoker
Previous PCI of noninfarct vessel
Time from onset of chest pain to admission, min
Median
Interquartile range
Infarct-related vessel
Left anterior descending coronary artery
Right coronary artery
Left circumﬂex coronary artery
Extent of coronary disease
1-vessel
2-vessel
3-vessel
Ejection fraction, %
Stents implanted, n
Pre-procedure quantitative coronary analysis
Angiograms evaluated, n
TIMI ﬂow grade 0 or 1
Diameter of reference vessel, mm
Minimal luminal diameter, mm
Post-procedure quantitative coronary analysis
Angiograms evaluated, n
TIMI ﬂow grade 3
Diameter of reference vessel, mm
Minimal luminal diameter, mm
In stent
In lesion
Stenosis, % of luminal diameter
In stent
In lesion
Successful treatment of lesion
Baseline clinical and procedural characteristics, quantitative coronary a
complete follow-up. Values given are n (%), unless otherwise indicated
of rounding. Differences in the numbers of patients whowere evaluate
of lesions are due to angiograms that could not be evaluated. Succes
stenosis of 50% of the luminal diameter and a coronary blood flow
classification, as assessed by the core laboratory. Differences in the nu
deaths of patients before each follow-up and to missing data.
PCI percutaneous coronary intervention.here was no difference in all stent thrombosis between rroups, although the number of events was numerically
igher in the BMS group due to a higher rate of unex-
lained deaths occurring after 30 days (13 and 21 in the SES
nd BMS groups, respectively; p 0.16; HR: 0.62; 95% CI:
.32 to 1.20).
The clinical presentation of very late stent thrombosis was
plete Follow-Up
n  211)
Complete Follow-Up
(n  501) p Value
9.3 13.2 59.2 11.7 0.945
164 (77.7) 394 (78.6) 0.842
40 (19.0) 76 (15.2) 0.222
79 (37.4) 210 (41.9) 0.278
87 (41.2) 213 (42.5) 0.803
5/192 (59.9) 241/472 (51.1) 0.140
9 (4.3) 21 (4.2) 1.000
0.616
175 180
110–300 120–295
0.377
102 (49.5) 218 (43.7) 0.270
76 (36.9) 206 (41.3) 0.483
27 (13.1) 73 (14.6) 0.840
0.960
113 (53.6) 263 (52.5) 0.806
69 (32.7) 170 (33.9) 0.795
29 (13.7) 68 (13.6) 1.000
0.4 11.7 53.3 11.1 0.003
1.2 0.5 1.1 0.4 0.120
199 495
126 (63.3) 338 (68.3) 0.213
2.7 0.5 2.9 0.6 0.052
0.2 0.3 0.2 0.3 0.633
202 495
195 (96.5) 473 (95.6) 0.678
2.9 0.5 3.0 0.5 0.060
2.5 0.4 2.6 0.4 0.041
2.3 0.5 2.3 0.5 0.921
3.3 8.2 12.8 8.0 0.519
8.6 9.1 19.5 8.9 0.212
190 (96.0) 458 (95.6) 1.000
and use ofmedication during the first year in patients with or without
inus values aremean SD. Percentagesmight not total 100, because
espect to quantitative coronary analysis and the successful treatment
atment of lesions was defined as the achievement of a final residual
de 3, according to the Thrombolysis In Myocardial Infarction (TIMI)
of patients who were evaluated for medications used are due to thetics
o Com
(
5
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5
1
1
nalysis
. Plus–m
dwith r
sful tre
of gra
mberse-MI in all cases. For 2 SES patients and 1 BMS patient,
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18Figure 2. Efficacy and Safety End Points at 4 Years(A) Freedom from target lesion revascularization. (B) Freedom from target vessel revascularization. Continued on the next page.
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19Figure 2. Continued
(C) Freedom from all-cause death. (D) Freedom from cardiac death. Error bars indicate a point-wise 2-sided 95% conﬁdence interval (CI) (1.96  standard error).
The standard error is based on the Greenwood formula. BMS  bare-metal stent(s); HR  hazard ratio.
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20ery late stent thrombosis happened despite receipt of dual
ntiplatelet therapy (DAPT) at the time of the event. In the
ES group, 3 patients who stopped clopidogrel in accor-
ance with the protocol at 6 months (2) or at 1 year (1)
xperienced a very late stent thrombosis at 17 months, 20
onths, and 4 years, respectively. In the BMS group, 2
atients stopped their clopidogrel intake at 20 and 32
onths after the index procedure. They experienced a very
ate stent thrombosis at 25 and 37 months, respectively.
All-cause death was analyzed in the 580 patients with
nown survival status at 4 years (survival status popula-
ion). Seventeen deaths occurred in the SES group, and
0 deaths occurred in the BMS group (5.8% and 7.0%,
espectively; p  0.61). The all-cause death rate in the
urvival status population was similar to that of the 501
atients with complete follow-up with no difference
etween the SES and BMS groups (4.0% and 6.4%, p 
8 
(3.2%)
2 
(0.8%)
BMS
Early (0 to 30 days) Very Late (> 1year)
10 (4%)
4 
(1.6%)
5
(2.0%)
CYPHER®
p=0.82
9 (3.6%)
HR [95% CI] = 0.90 [0.37, 2.17]
-1% 0% 1% 2% 3% 4% 5% 6% 7% 8%
9 
(3.6%)
3 
(1.2%)
BMS
Early (0 to 30 days) Very Late (> 1year)
12 (4.8%)
6 
(2.4%)
5
(2.0%)
CYPHER®
p=0.83
11 (4.4%)
HR [95% CI] = 0.91 [0.41, 2.03]
0.0% 1.0% 2.0% 3.0% 4.0% 5.0% 6.0% 7.0% 8.0%
9 
(3.6%)
3 
(1.2%)
9
(3.6%)
BMS
Early (0 to 30 d) Late (>30 d to 1 yr) Very Late (> 1yr)
21 (8.4%)
6 
(2.4%)
1
(0.4%)
6
(2.4%)
CYPHER®
p=0.16
13 (5.2%)
HR [95% CI] = 0.62 [0.32, 1.20]
0% 2% 4% 6% 8% 10%
A
B
C
Figure 3. Stent Thrombosis at 4 Years
(A) Deﬁnite stent thrombosis. (B) Deﬁnite/probable stent thrombosis. (C)
Deﬁnite/probable/possible stent thrombosis. Numbers indicate the number
of stent thrombosis cases with the percentage in parentheses. ARC  Aca-
demic Research Consortium; other abbreviations as in Figure 2..23) (Figs. 1 and 4).Use of medication was similar between groups (Table 2).
t 4 years, 19% of patients in the SES group and 15.7% in
he BMS group were receiving DAPT (p  0.40). Most
atients were taking only 1 antiplatelet drug.
iscussion
n this randomized trial comparing the use of SES and
MS in the setting of STEMI, the benefit of SES in
educing repeat revascularization was maintained at 4 years
n the 70% of patients with complete follow-up, with no
ifference in all-cause death, cardiac death, recurrent MI, or
tent thrombosis.
Over 7,000 patients have been randomized in studies
omparing DES and BMS in the setting of primary PCI for
TEMI. A reduction in repeat revascularization had been
ound in all with no increase in death, recurrent MI, or stent
hrombosis at 1 year (23). Registries have generated con-
icting data. In a large state-based registry, Mauri et al. (19)
oted significant differences in repeat revascularization and
decrease in all-cause death favoring DES. In contrast, Steg
t al. (20) noted an increase of death at 2 years in patients
ith acute MI and implantation of a DES during the initial
ospital stay.
Very late stent thrombosis after DES implantation has been
eported to occur at a rate of 0.2% to 0.6%/year (24,25,26).
athological studies have shown that lack of complete endo-
helialization might be a leading cause of DES late thrombosis
27,28). Furthermore, Nakazawa et al. (29) demonstrated that
essel healing at culprit sites of plaque rupture is substantially
educed compared with culprit sites of stable lesions. There-
ore, the use of DES during primary PCI for acute MI remains
ighly controversial.
The results of our long-term follow-up are similar to
hose of 2 smaller randomized trials. In the STRATEGY
Single High-Dose Bolus Tirofiban and Sirolimus Eluting
tent Versus Abciximab and Bare Metal Stent in Acute
yocardial Infarction) trial, patients were randomized to
eceive a SES or a BMS (5,17). At 5 years, the primary end
10
15
20
CYPHER® BMS
%
 o
f
0 61
4.0
5.86.4
7.0
0
5
f 
Pa
tie
nt
s
p=0.23 p= .
Complete Follow-Up Population 
501/712 (71%)
Survival Status Population     
580/712 (81%)
Figure 4. All-Cause Death in Survival Status and Complete Follow-Up
PopulationBMS  bare-metal stent.
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21oint (composite of death, MI, stroke, or binary restenosis)
emained lower in the SES group (30% vs. 51%; p 0.006).
ll-cause mortality and the composite of death or MI were
imilar in the SES and BMS groups (p  0.70 and p 
.58, respectively), whereas the need for TVR remained
arkedly reduced (10.3% vs. 26.1%; p  0.007) in the SES
roup. The cumulative incidence of definite, probable, or
ossible stent thrombosis was 6.9% in the SES group versus
.9% in the BMS group (p  0.99). In the PASEO
PaclitAxel or Sirolimus-Eluting Stent vs. Bare Metal Stent
n Primary Angioplasty) trial, 270 patients with STEMI
ere randomized to BMS, paclitaxel-eluting stent, or SES
16). At the long-term follow-up (4.3 years; 25th to 75th
ercentile, 3.7 to 5 years), no difference was observed in
erms of death, reinfarction, and combined death and/or
einfarction, but compared with BMS (22.2%), both
aclitaxel-eluting stent (6.7%; HR: 0.27; 95% CI: 0.11 to
.68; p  0.005) and SES (5.6%; HR: 0.22; 95% CI: 0.083
o 0.59; p  0.003) were associated with a significant
eduction in TLR. Therefore, the current data support the
ong-term efficacy and safety of DES implanted during
rimary PCI for STEMI.
Guidelines recommend DAPT for 1 year after DES
mplantation in patients who are not at high risk for
leeding (30). Screening patients for prolonged DAPT in
he setting of primary PCI for acute MI might be difficult.
n the PREMIER (Prospective Registry Evaluating Myo-
ardial Infarction: Events and Recovery), almost 1 in 7 acute
I patients who received a DES were no longer taking
hienopyridines by 30 days. Prematurely stopping thienopy-
idine therapy was strongly associated with subsequent
ortality (31). In the TYPHOON trial, the protocol
andated 6 months of DAPT in both groups, which could
e continued at the investigator’s discretion. The average
uration of thienopyridine therapy was 9.7 2.9 months in
he SES group and 9.5  3.1 months in the BMS group,
 0.37). At 4 years, only 19% and 15.7%, respectively,
ere receiving DAPT (p  0.40). The majority of the
opulation was taking a single antiplatelet drug. No com-
lication occurred due to premature discontinuation of
hienopyridine therapy or bleeding complications occurred
ue to the use of DAPT in patients with nonrecognized
Table 2. Medication Status at 4-Year Follow-Up
All Patients
(n  501)
DAPT 83/478 (17.4%)
Aspirin 402/478 (84.1%)
Clopidogrel 137/477 (28.7%)
Ticlopidine 4/477 (0.8%)
Single antiplatelet therapy (%) 459/478 (96.0%)
BMS bare metal stent(s); DAPT dual antiplatelet therapy; Single are-existing comorbidities. The debate over the prescription ff prolonged DAPT after implantation of a DES during
rimary PCI for STEMI is overshadowed by the benefits of
uch therapy in patients with acute coronary syndromes
32). Given the demonstrated benefits in acute coronary
yndromes, current guidelines on the management of
TEMI recommend DAPT for 1 year after primary PCI,
egardless of the type of stent implanted (1,2). Therefore, in
cute MI treated by primary PCI, patient education should
mphasize the importance of compliance to long-term
APT in all patients, whether or not a DES has been
mplanted.
The stent thrombosis rates at 1 year in both groups were
igher than those noted in previous studies performed in
on-STEMI patients (33). Similar rates were noted in
revious studies comparing DES with BMS in STEMI
atients (5–14). Acute coronary syndrome has been de-
cribed as a predictor of stent thrombosis (34). The
RITON–TIMI 38 (Trial to Assess Improvement in Ther-
peutic Outcomes by Optimizing Platelet Inhibition with
rasugrel–Thrombolysis in Myocardial Infarction 38) study
andomized 12,844 patients with moderate- to high-risk
cute coronary syndromes treated by PCI to clopidogrel or
rasugrel (35,36). Stent thrombosis rates increased accord-
ng to the risk profile and reached 2.8% in the STEMI
roup receiving clopidogrel after a median duration of
herapy of 14.5 months. No differences in thrombosis rates
ere noted between DES and BMS. The administration of
rasugrel resulted in a 21% reduction of stent thrombosis.
herefore, stent thrombosis is a concern after primary PCI
or STEMI in all patients, irrespective of stent type, and
ffective platelet inhibition is important to reduce the rate of
his dramatic event.
tudy limitations. Target lesion and vessel revascularization
ates during the first year were higher than other studies,
uch as the HORIZONS AMI (Harmonizing Outcomes
ith RevasculariZatiON and Stents in Acute Myocardial
nfarction) trial (13). This finding might be related to the
ffect of angiographic follow-up in a subgroup of patients,
ecause revascularization rates tended to be higher among
atients undergoing follow-up angiography.
The numbers of patients with incomplete data are high.
ifferences in baseline and procedural characteristics were
CYPHER
(n  251)
BMS
(n  250) p Value
46/242 (19.0%) 37/236 (15.7%) 0.40
201/242 (83.1%) 201/236 (85.2%) 0.53
77/242 (31.8%) 60/235 (25.5%) 0.16
2/242 (0.8%) 2/235 (0.9%) 1.00
234/242 (96.7%) 225/236 (95.3%) 0.49
let therapy aspirin and/or clopidogrel and/or ticlopidine.ound between patients with or without complete follow-up.
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22n particular, left ventricular ejection fraction, which is
ssociated with long-term mortality after MI, was lower in
atients lost to follow-up. Of note, the rate of all-cause
eath was similar in patients with complete follow-up and
hose with only survival status available. Because of the high
umber of patients lost to follow-up, we performed addi-
ional statistical analysis to assess the importance of missing
ata on our results (tipping point analysis and missing data
mputation, see Online Appendix). This analysis suggested
hat the efficacy end points (TLR and TVR) were not
ensitive to the missing data, in contrast to the safety end
oints. A bias due to a high rate of missing data, however,
annot be excluded. Furthermore, the study was underpow-
red to assess rare events, such as stent thrombosis.
Our results cannot be generalized to all patients with
TEMI, because high-risk patients were excluded and a
lass effect across other DES should not be assumed.
inally, follow-up was stopped at 4 years, and very long-
erm outcome is unknown.
onclusions
n the 70% of patients enrolled in the TYPHOON trial
ith complete 4-year follow-up, the SES demonstrated
ustained efficacy to reduce TLR with no difference in
eath, repeat MI, or stent thrombosis.
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